ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development Post author: Post published:November 13, 2023 Post category:uncategorized ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. You Might Also Like Next-gen implants could be powered by dual-energy harvesting technology February 24, 2024 Father’s diet before conception can impact children’s metabolic health, study finds June 7, 2024 New study reveals cefoxitin as effective first-line treatment for intraamniotic infections February 5, 2024
New study reveals cefoxitin as effective first-line treatment for intraamniotic infections February 5, 2024